Which patient profiles constitute absolute contraindications to stimulant therapy for attention-deficit/hyperactivity disorder?

Absolute Contraindications to Stimulant Therapy in ADHD

Stimulant medications are absolutely contraindicated in patients currently taking MAO inhibitors, those with active psychotic disorders (schizophrenia, psychosis NOS, or manic episodes with psychosis), patients with glaucoma, and those with recent stimulant abuse or dependence unless in a controlled/supervised setting. 1

Core Absolute Contraindications

Based on the AACAP Practice Parameters, the following patient profiles constitute absolute contraindications:

1. Concomitant MAO Inhibitor Use

• This is the most dangerous contraindication
• Severe hypertensive crisis will result with risk of cerebrovascular accident (stroke)
• No exceptions to this rule 1

2. Active Psychotic Disorders

• Patients with schizophrenia, psychosis NOS, or manic episodes with psychosis
• Stimulants are known psychotomimetics that will exacerbate psychotic symptoms
• The guidelines explicitly note that FDA package inserts fail to adequately emphasize this as a true contraindication 1

3. Glaucoma

• Sympathomimetic effects may increase intraocular pressure
• Applies to all stimulant medications 1

4. Recent Stimulant Abuse or Dependence

• Black box warning for methylphenidate, dextroamphetamine, and amphetamine
• Exception: May be used in controlled settings with close supervision
• Important nuance: History of other substance abuse (alcohol, opiates, benzodiazepines, cigarettes) is NOT an absolute contraindication, though requires careful monitoring 1

5. Previous Hypersensitivity to Stimulants

• Prior allergic or severe adverse reactions 1

Serious Relative Contraindications (Use with Extreme Caution)

Cardiovascular Conditions

• Symptomatic cardiovascular disease
• Hypertension (uncontrolled)
• Hyperthyroidism 1
• Personal or family history of sudden cardiac death, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, or long QT syndrome 2

Liver Disease (Pemoline-Specific)

• Pemoline should not be used with preexisting liver disease or abnormal liver function tests due to documented hepatotoxicity 1

Important Clinical Pitfalls

Common misconceptions about contraindications that are NOT absolute:

• Motor tics/Tourette's syndrome: FDA package inserts list this, but controlled studies show methylphenidate does not worsen tics in most patients 1
• Anxiety disorders: Actually improve with stimulants in comorbid ADHD 1
• Seizure disorders: Not contraindicated once stabilized on anticonvulsants 1
• Depression: Caution needed with unstable mood disorders, but not absolute contraindication 1
• Age under 6: Package insert warning, but 8 published studies show methylphenidate efficacy in preschoolers 1

Algorithmic Approach to Screening

Before prescribing stimulants, systematically assess:

1. Current medications: Any MAO inhibitors? → Absolute stop
2. Psychiatric status: Active psychosis or mania? → Absolute stop
3. Ophthalmologic: Glaucoma diagnosis? → Absolute stop
4. Substance use: Recent stimulant abuse/dependence AND not in controlled setting? → Absolute stop
5. Allergy history: Prior stimulant hypersensitivity? → Absolute stop
6. Cardiac screening: Obtain personal/family cardiac history; if positive risk factors present, obtain ECG before proceeding 2
7. Cardiovascular exam: Symptomatic heart disease, uncontrolled hypertension, hyperthyroidism? → High caution, consider alternatives

The evidence strongly emphasizes that many traditional "contraindications" from package inserts are not supported by clinical trial data and should not prevent appropriate treatment 1.